ADNT Insider Notice: 12,000 RSU Shares to Be Sold via Oppenheimer on NYSE
Rhea-AI Filing Summary
Adient plc submitted a Form 144 disclosing a proposed sale of 12,000 common shares acquired as restricted stock units on 11/18/2022. The shares are to be sold through Oppenheimer & Co. Inc. on the NYSE with an approximate aggregate market value of $271,119.00 and total shares outstanding listed as 81,245,928. The filing shows no securities sold by the reporting person in the past three months. The notice includes the signer’s representation that they are not aware of any undisclosed material adverse information about the issuer.
Positive
- Planned sale disclosed: 12,000 common shares announced for sale, providing market transparency
- Broker and exchange identified: Oppenheimer & Co. on the NYSE with an aggregate market value of $271,119.00
- Acquisition method disclosed: Shares were acquired as RSUs on 11/18/2022, with payment recorded on the same date
Negative
- Filer identifiers missing: CIK and submission contact fields are empty in the provided content
- Limited context on seller: The filing does not include additional narrative about the reason or any trading plan dates beyond the attestation
Insights
TL;DR: Routine insider notice: 12,000 Adient shares proposed for sale via Oppenheimer, disclosed under Rule 144.
The Form 144 is a standard regulatory disclosure identifying a proposed sale of 12,000 common shares with an aggregate market value of $271,119. It specifies the broker (Oppenheimer & Co.) and the target exchange (NYSE), and notes the shares were acquired as RSUs on 11/18/2022. The filing reports no sales in the past three months and includes the customary representation regarding undisclosed material adverse information. This filing is procedural and provides transparency about an intended insider sale.
TL;DR: Disclosure follows Rule 144 mechanics; identifies acquisition type, broker, and outstanding shares but omits filer contact details.
The notice documents key compliance elements: the nature of acquisition (RSU), acquisition and payment dates (11/18/2022), and the planned sale date (08/07/2025). It confirms the broker and exchange. However, fields for filer CIK and contact information appear blank in the provided content, which limits immediate on-file identification of the reporting person. The form includes the required signer attestation about material information.
FAQ
What does the Adient (ADNT) Form 144 disclose?
When were the shares acquired that are being sold under Form 144?
What is the approximate date of the planned sale in the Form 144 for ADNT?
How many shares outstanding does the filing list for Adient?
Were any securities sold in the past three months by the reporting person?
Does the Form 144 include a broker name and address?